Relationship between False Positive Screening Results of Down Syndrome and Adverse Pregnancy Outcomes

Maryam Honarjoo, Shahnaz Kohan, Mohammad Javad Tarrahi, Elahe Zarean, Soheila Sepahi, Zeinab Safar

Abstract


Background: Maternal serum sample screening in the first and second trimesters has been commonly used to identify women who are at risk of fetal trisomy 21. In addition, these serum markers are associated with adverse perinatal outcomes. Hence, the present study was conducted to determine the relationship between false positive screening results of Down syndrome and adverse pregnancy outcomes.

 Material and Methods: This prospective, two‑group, cohort study was conducted on 608 pregnant women who had undergone fetal contingent screening. They were selected through convenience sampling in the twentieth week of pregnancy and were followed up until delivery. The raw Odd Ratios (OR), Relative Risk (RR), and adjusted OR of adverse pregnancy outcomes were calculated in the false positive and true negative groups.

Results: The adjusted OR of developing preeclampsia was 1.98 (95% CI: 1.14–3.42), and its RR was 2.13 (95% CI: 1.34–3.38) times higher in the false positive group. Moreover, the adjusted OR of Small for Gestational Age (SGA) was 2.80 (95% CI: 1.76–4.47), and its RR was 2.28 (95% CI: 1.54–3.36) times higher in the false positive group. The adjusted OR of Low Birth Weight (LBW) was 3.34 (95% CI: 1.97–5.64), and its RR was 2.65 (95% CI: 1.72–4.11) times higher in the false positive group. In addition, no significant difference was observed between false positive and true negative groups in terms of preterm birth.

Conclusions: Women with a false positive fetal screening test result are more likely to suffer from preeclampsia, SGA, and LBW and require planned prenatal care.

Keywords:


Keywords


Adverse pregnancy outcomes, Down syndrome screening, low birth weight, small for gestational age

Full Text:

PDF

References


American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins Obstetrics; Committee on Genetics; Society for Maternal Fetal Medicine. Screening for fetal chromosomal abnormalities: ACOG Practice bulletin, Number 226. Obstet Gynecol 2020;136:e48 9.

Pylypjuk CL, Monarrez Espino J. False positive maternal serum screens in the second trimester as markers of placentally mediated complications later in pregnancy: A systematic review and meta analysis. Dis Markers 2021;2021:5566234.

Gomes MS, Carlos Alves M, Trocado V, Arteiro D, Pinheiro P. Prediction of adverse pregnancy outcomes by extreme values of first trimester screening markers. Obstet Med 2017;10:132 7.

Honarjoo M, Zarean E, Tarrahi MJ, Kohan S. Role of pregnancy associated plasma protein A (PAPP A) and human derived chorionic gonadotrophic hormone (free β hCG) serum levels as a marker in predicting of Small for gestational age (SGA): A cohort study. J Res Med Sci 2021;26:104.

Kaijomaa M, Rahkonen L, Ulander VM, Hämäläinen E, Alfthan H, Markkanen H, et al. Low maternal pregnancy-associated plasma protein A during the first trimester of pregnancy and pregnancy outcomes. Int J Gynecol Obstet 2017;136:76 82.

Yee L, Valderramos SG, Pena S, Cheng YW, Bianco K. Perinatal outcomes in euploid pregnancies with ‘double positive’first trimester prenatal screening for trisomy 18 and 21. J Perinatol 2013;33:836 40.

Dugoff L; Society of Maternal Fetal Medicine. First and second trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol 2010;115:1052 61.

Gagnon A, Wilson RD; Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Canada 2008;30:918 32.

Cohen JL, Smilen KE, Bianco AT, Moshier EL, Ferrara LA, Stone JL. Predictive value of combined serum biomarkers for adverse pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2014;181:89 94.

Goetzl L Adverse pregnancy outcomes after abnormal first trimester screening for aneuploidy. Clin Lab Med 2010;30:613 28.

Gundu S, Kulkarni M, Gupte S, Gupte A, Gambhir M, Gambhir P. Correlation of first trimester serum levels of pregnancy associated plasma protein A with small for gestational age neonates and preterm births. Int J Gynecol Obstet 2016;133:159 63.

Honarjoo M, Kohan S, Zarean E, Tarrahi MJ. Assessment of β human derived chorionic gonadotrophic hormone (βhCG) and pregnancy associated plasma protein A (PAPP A) levels as predictive factors of preeclampsia in the first trimester among Iranian women: A cohort study. BMC Pregnancy Childbirth 2019;19:1 5.

Yazdani S, Rouholahnejad R, Asnafi N, Sharbatdaran M, Zakershob M, Bouzari Z. Correlation of pregnancy outcome with quadruple screening test at second trimester. Med J Islam Repub Iran 2015;29:281.

Baer RJ, Currier RJ, Norton ME, Flessel MC, Goldman S, Towner D, et al. Obstetric, perinatal, and fetal outcomes in pregnancies with false positive integrated screening results. Obstet Gynecol 2014;123:603 9.

Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000;107:1265 70.

Pergament E, Stein AK, Fiddler M, Cho NH, Kupferminc MJ. Adverse pregnancy outcome after a false positive screen for Down syndrome using multiple markers. Obstet Gynecol 1995;86:255 8.

Spencer K, Cowans NJ, Avgidou K, Nicolaides KH. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 2006;28:637 43.

Sritippayawan S, Vachirasrisoontra C. Adverse pregnancy outcomes after a false positive second trimester serum screen for Down syndrome in Thai pregnant women. J Med Assoc Thai 2005;88:449 54.


Refbacks

  • There are currently no refbacks.